Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AdvisorShares Psychedelics ETF PSIL

The AdvisorShares Psychedelics ETF (the Fund) seeks long-term capital appreciation. The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid, small and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies.


ARCA:PSIL - Post by User

AdvisorShares Psychedelics ETF
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(273)
•••
Post by partystockeron Nov 21, 2021 4:53pm
181 Views
Post# 34151083

$ORIG news

$ORIG news

Origin Therapeutics has released their official leadership team. Looks like a lot of experienced individuals in the psychedelics and financial fields. I’m looking forward to seeing how they further build out their portfolio in such a budding industry. 


From their investor presentation, it seems like Origin will be a pretty solid way to get some exposure to the psychedelic industry through a well-vetted approach. They also boast zero management fees, unlike Horizons PSYK ETF.


https://originpsychedelics.com/newsroom/origin-therapeutics-announces-leadership-team/

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities